最新ニュース Orange (OTC:ORANY) 株価情報

Orange is the incumbent telecom operator in France. The company operates fixed and wireless businesses in France, where it is the market leader ahead of Iliad, Bouygues, and SFR. Orange also has fixed and wireless (convergent) operations in Spain, Poland, Belgium, Luxembourg, and Central Europe (Romania, Slovakia, Moldova). Around 15% of revenue comes from emerging African markets, where the company only operates wireless networks, and 20% comes from the enterprise segment, which serves companies with more than 50 employees in France and internationally.

Orange SA

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower Monday as investors react to rising macroeconomic uncertainty following U.S. President Donald Trump&#8216;s confirmation of <a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">new tariffs.</a>
What To Know: Trump announced plans to impose 25% tariffs on imports from Canada and Mexico and 20% tariffs on Chinese imports, set to take effect on Tuesday. The move raises concerns about increased costs for American consumers and the potential for higher inflation.
Economic data has already shown signs of weakness, with consumer spending declining in January and some GDP forecasts turning negative. Inflation remains above the Federal Reserve's 2% target, with the Consumer Price Index rising 3% in January, exceeding economist expectations.
While Treasury Secretary Scott Bessent downplayed the inflationary impact of the tariffs, suggesting that China would absorb the costs, market participants remain cautious. St. Louis Federal Reserve President Alberto Musalem indicated that near-term inflation expectations have "risen substantially" in recent weeks.
The Federal Reserve has held interest rates steady at a target range of 4.25% to 4.5% since January and the probability of maintaining this range at the next meeting remains at 93%, according to the CME Group&#8217;s FedWatch tool.
TSLA Price Action: Tesla shares were down 2.84% at $284.65 when the market closed Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="539" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03160405/Screenshot-2025-03-03-at-16.03.40-1024x539.png" alt="" class="wp-image-806859" style="width:371px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03160405/Screenshot-2025-03-03-at-16.03.40-1024x539.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03160405/Screenshot-2025-03-03-at-16.03.40-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03160405/Screenshot-2025-03-03-at-16.03.40-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03160405/Screenshot-2025-03-03-at-16.03.40.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li><a href="https://www.benzinga.com/25/03/44093347/4-stocks-to-buy-on-chinas-huge-stimulus">4 Stocks to Buy on China&#8217;s Huge Stimulus</a></li>
</ul>
Image Via Shutterstock.

News

Movers

TSLA

Tesla Shares Decline Amid Concerns Over Trump's Tariff Plans

BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) sees FY2025 sales of $395.000 million-$425.000 million vs $414.85 million analyst estimate.

Guidance

BRCC

BRC Sees FY2025 Sales $395.000M-$425.000M vs $414.85M Est

Management

Xcel Energy COO Timothy O'Connor To Retire

AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. &nbsp;The company reported quarterly sales of $1.92 million.

Earnings

Earnings Misses

ASTS

AST SpaceMobile Q4 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $1.92M

NuScale Power Q4 Sales $34.2M

BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 200 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $105.88 million which missed the analyst consensus estimate of $106.20 million by 0.30 percent. This is a 11.51 percent decrease over sales of $119.65 million the same period last year.

BRC Q4 EPS $(0.03) Misses $(0.01) Estimate, Sales $105.88M Miss $106.20M Estimate

Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.26 by 7.69 percent. This is a 33.33 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $40.800 million which beat the analyst consensus estimate of $38.766 million by 5.25 percent. This is a 8.73 percent increase over sales of $37.524 million the same period last year.

Earnings Beats

Whitestone REIT Q4 2024 FFO $0.28 Beats $0.26 Estimate, Sales $40.800M Beat $38.766M Estimate

Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) sees Q1 sales of $65.000 million-$68.000 million vs $63.07 million analyst estimate.

Viant Technology Sees Q1 Sales $65.000M-$68.000M vs $63.07M Est

SENS

Senseonics Holdings Sees FY25 Revenue $34M-$38M

New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.04 by 225 percent. This is a 87.13 percent decrease over earnings of $1.01 per share from the same period last year.

New Fortress Energy Q4 Adj $0.13 Beats $0.04 Estimate

WIIM

ADMA

ADMA Biologics shares are trading higher following better-than-expected Q4 revenue results.

Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.12 by 25 percent. This is a 7.14 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $90.05 million which beat the analyst consensus estimate of $83.96 million by 7.25 percent. This is a 39.82 percent increase over sales of $64.41 million the same period last year.

Viant Technology Q4 Adj $0.15 Beats $0.12 Estimate, Sales $90.05M Beat $83.96M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) has outperformed the market over the past 10 years by 1.83% on an annualized basis producing an average annual return of 12.87%. Currently, Globus Medical has a market capitalization of $10.90 billion. 
Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $331.87 today based on a price of $79.25 for GMED at the time of writing.
<h3>Globus Medical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741036509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GMED

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Ameresco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) stock traded lower on Monday. The company announced the acquisition of ASA Controls, an Ohio-based company specializing in building automation <a href="https://www.benzinga.com//node/44075209">and control systems</a>.
The Details: With this acquisition, Ameresco expands its existing portfolio and solution offerings in the smart buildings sector. The financial details of the acquisition have not been released, but Ameresco does not anticipate that the deal will impact its 2025 fiscal results.
&#8220;We are thrilled to welcome ASA Controls to the Ameresco family,&#8221; said Lou Maltezos, President of Central &amp; Western USA, Canada Regions at Ameresco.
&#8220;This acquisition aligns with our strategic goals and strengthens our ability to deliver innovative building automation solutions to our clients. The combined expertise and resources of our teams will enable us to tackle larger, more complex projects and drive significant value for our customers.&#8221;
See Also: <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/03/44089512/3-china-focused-etfs-to-watch-as-stronger-manufacturing-data-stimulus-hopes-boost-senti">3 China-Focused ETFs To Watch As Stronger Manufacturing Data, Stimulus Hopes Boost Sentiment</a>
AMRC Price Action: Ameresco shares closed 10.5% lower at $10.56 on Monday, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

AMRC

What's Going On With Ameresco Shares Monday?

NIO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock traded lower on Monday. Weakness in the stock may be in anticipation of U.S. tariffs, expected to <a href="https://www.benzinga.com//node/44070271">begin on Tuesday.</a>
The Details: According to <a href="https://www.cbsnews.com/news/trump-tariffs-canada-mexico-inflation-us-economy/">CBS</a>, President Donald Trump announced on social media in late February that 25% tariffs on Canada and Mexico will begin on March 4. Furthermore, an additional 10% tariff on Chinese imports is set to take effect this week.
Beginning on March 12, Trump plans to impose 25% tariffs on steel and aluminum imports. Trump may also deploy reciprocal tariffs and levies on automobile imports in early April and has threatened to institute 25% duties on imports from the European Union.
&#8220;Normally I&#8217;d say tariffs alone would damage the economy, but won&#8217;t send the U.S. into recession,&#8221; Marcus Noland, director of studies at the Peterson Institute for International Economics, told CBS.
&#8220;What gives me pause about that now is the unsettling way that the administration is going about its business and general confusion about tariffs. It&#8217;s not so much the actual tariffs but confusion about them that&#8217;s causing an increase in uncertainty and is really pushing down investment,&#8221; he added.
Consumer sentiment suffered a <a href="https://www.benzinga.com/25/02/43923691/whats-going-on-with-nio-shares-monday">significant setback</a>. The University of Michigan consumer sentiment index plummeted to 64.7 in February, marking a 10% decline. This downturn reflects growing consumer concerns about rising inflation and the potential impact of impending tariffs.
NIO shares may be falling as investors anticipate increased costs for the Chinese electric vehicle manufacturer. In addition, the general uncertainty around trade policy and tariffs has created volatility in the market.
Price Action: NIO stock closed 8.92% lower at $4.22, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Related Link: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44088403/amazon-web-services-bets-big-on-india-with-82-billion-cloud-investment">Amazon Web Services Bets Big On India with $8.2 Billion Cloud Investment</a></li>
</ul>
Image: Courtesy of NIO, Inc.

What's Going On With NIO Shares Monday?

ADMA Biologics Q4 2024 Adj. EPS $0.14 Misses $0.15 Estimate

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $8.30 million which beat the analyst consensus estimate of $7.86 million by 5.60 percent. This is a 3.75 percent increase over sales of $8.00 million the same period last year.

Senseonics Holdings Q4 2024 GAAP EPS $(0.03), Inline, Sales $8.30M Beat $7.86M Estimate

GENC

Gencor Sees Prelim. 2024 Revenue $113M, Up From $105.1M YoY

Tenaya Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Biotech

Offerings

General

TNYA

Tenaya Therapeutics Announced Intention To Offer Common Stock, Series A & B Warrants

Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer;&nbsp;Roy Galvin named Executive Vice President, Chief Commercial Officer
BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately.
As Chief Operating Officer, Chan will direct Haemonetics' research and development as well as regulatory affairs, driving innovation and operational excellence to support the company's growth.&nbsp;He will also oversee Haemonetics' global manufacturing and supply chain operations. He will report to&nbsp;Chris Simon, Haemonetics' President and Chief Executive Officer.

Haemonetics Announces Executive Leadership Updates; Frank Chan Joins Haemonetics As Executive Vice President, Chief Operating Officer, Effective April 7, 2025

Comments

Orange

ニュース

最新ニュース Orange (OTC:ORANY) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル